Emyria Ltd (ASX:EMD) managing director Michael Winlo chats with Proactive about a collaboration with PsychoGenics, a specialist neuroscience, drug discovery company based in New Jersey USA. The partnership will aid in advancing Emyria’s MDMA-inspired new drug discovery program. Winlo discusses phase 3 approval for MDRX5. “Given the increasing research and investment into novel neurological drugs and psychedelic-assisted therapies, we are excited to accelerate the identification of promising neuropsychiatric drugs and next-generation psychedelic-assisted therapies for further evaluation."
Emyria welcomes key collaboration with leading neuroscience drug discovery research organisation
